CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis

Recruiting now · Not applicable

Conditions studied: Decompensated Cirrhosis

In brief

The CirrhoCare trial is a multi-centre, open label randomised controlled trial in patients with decompensated cirrhosis. The trial aims to investigate the clinical and cost-effectiveness of CirrhoCare digital home monitoring and management with current standard of care in these patients.

Key facts

Study ID

NCT06223893

Run by

University College, London

People needed

214

Starts

2023-11-24

Expected to finish

2027-01-31

Last updated by the study team

2026-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥ 18 years and diagnosed with cirrhosis of any aetiology.
• Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology. Cirrhosis of any aetiology may be included. However, participants with cirrhosis due to autoimmune hepatitis must be on a stable corticosteroid dose for ≥3-month period before study inclusion (to be recorded on concomitant log).
• Cirrhosis severity-risk defined by European-Foundation Consortium Liver Failure - Acute Decompensation score (CLIF-C AD score) ≥42 points but ≤65 points at the time of screening.
• Hospitalisation for acute decompensation [determined as one or more of the following: increasing ascites, variceal haemorrhage, overt hepatic encephalopathy, spontaneous bacterial peritonitis (SBP) or hepatorenal syndrome - acute kidney injury (HRS-AKI)].
• Participants able to give informed consent.

You may not qualify if…

• Participants with ACLF grade 2 and above according to the criteria published by Moreau
• Participants with CLIF-C AD score ≥ 66, who have a high mortality similar to ACLF ≥2 participants.
• Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the West-Haven classification, unable to give consent.
• Participants with active hepatocellular carcinoma (HCC) or history of HCC that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria.
• Participants with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD >2, chronic kidney disease with serum creatinine >2mg/dL or under renal replacement therapy.
• Participants with documented refractory ascites on a palliative pathway.
• Participants who are active on the transplant waiting list.
• Participants with current extra hepatic malignancies including solid tumours and hematologic disorders.
• Participants with mental incapacity, significant language barriers, or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.
• Participants with active viral infections, or yet to achieve clear response to anti-viral therapy.
• Any disorders likely to impact on study engagement, including severe frailty, severe addiction history (including opioids) with evidence of multiple recent relapses.
• Any other reason that the PI considers would make the participant unsuitable to enter CirrhoCare (e.g., participants on an end-of-life palliative care pathway).
• Participants enrolled in other interventional trials.

Where it is running

• Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust — Birmingham, United Kingdom (enrolling)
• Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust — Brighton, United Kingdom (enrolling)
• Walsgrave General Hospital, University Hospital Coventry & Warwickshire NHS Trust — Coventry, United Kingdom (enrolling)
• Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust — Liverpool, United Kingdom (enrolling)
• The Royal London Hospital, Barts Health NHS Trust — London, United Kingdom (enrolling)
• Whittington Hospital, Whittington Health NHS Trust — London, United Kingdom (enrolling)
• Royal Free Hospital, Royal Free London NHS Foundation Trust — London, United Kingdom (enrolling)
• Torbay Hospital, Torbay and South Devon NHS Foundation Trust — Torquay, United Kingdom (enrolling)
• King's College Hospital, King's College Hospital NHS Foundation Trust — London, United Kingdom (enrolling)
• St George's Hospital, St George's university Hospital NHS Foundation Trust — London, United Kingdom (enrolling)
• Queen's Medical Centre, Nottingham University Hospitals NHS Trust — Nottingham, United Kingdom (enrolling)
• John Radcliff Hospital, Oxford University Hospitals NHS Foundation Trust — Oxford, United Kingdom (enrolling)
• Derriford Hospital, University Hospitals Plymouth NHS Trust — Plymouth, United Kingdom (enrolling)
• Southampton General Hospital, University Hospital Southampton NHS Foundation Trust — Southampton, United Kingdom (enrolling)
• St Thomas Hospital, Liverpool University Hospitals NHS Foundation Trust — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.